Herkinorin analogues with differential β-arrestin-2 interactions

Journal of Medicinal Chemistry

Volumn 51, Issue 8, 2008, Pages 2421-2431

  Tidgewell, Kevin ^a   Groer, Chad K ^b   Harding, Wayne W ^a   Lozama, Anthony ^a   Schmidt, Matthew ^a   Marquam, Alfred ^a,c   Hiemstra, Jessica ^a   Partilla, John S ^d   Dersch, Christina M ^d   Rothman, Richard B ^d   Bonn, Laura M ^b   Prisinzano, Thomas E ^a,c,e  

^a UNIVERSITY OF IOWA   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e 4035 Malott Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 2; HERKINORIN; MU OPIATE RECEPTOR; OPIATE AGONIST; SALVINORIN A;

ANALGESIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; CHEMICAL MODIFICATION; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PROTEIN INTERACTION; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; STRUCTURE ACTIVITY RELATION;

ARRESTINS; CELL LINE; DITERPENES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 43049127171     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701162g     Document Type: Article

References (53)

1. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 2007, 320, 1-13.
2. von Zastrow, M.; Svingos, A.; Haberstock-Debic, H.; Evans, C. Regulated endocytosis of opioid receptors: Cellular mechanisms and proposed roles in physiological adaptation to opiate drugs. Curr. Opin. Neurobiol. 2003, 13, 348-353.
3. Bohn, L. M.; Dykstra, L. A.; Lefkowitz, R. J.; Caron, M. G.; Barak, L. S. Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol. Pharmacol. 2004, 66, 106-112.
4. Bohn, L. M.; Lefkowitz, R. J.; Gainetdinov, R. R.; Peppel, K.; Caron, M. G.; Lin, F. T. Enhanced morphine analgesia in mice lacking beta-arrest in 2. Science 1999, 286, 2495-2498.
5. Bohn, L. M.; Gainetdinov, R. R.; Lin, F. T.; Lefkowitz, R. J.; Caron, M. G. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000, 408, 720-723.
6. Bohn, L. M.; Lefkowitz, R. J.; Caron, M. G. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J. Neurosci. 2002, 22, 10494-10500.
7. Raehal, K. M.; Walker, J. K. L.; Bohn, L. M. Morphine side effects in β-arrestin 2 knockout mice. J. Pharmacol. Exp. Ther. 2005, 314, 1195-1201.
8. Kohout, T. A.; Lefkowitz, R. J. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol. Pharmacol. 2003, 63, 9-18.
9. Zuo, Z. The role of opioid receptor internalization and beta-arrestins in the development of opioid tolerance. Anesth. Analg. 2005, 101, 728-734.
10. Ortega, A.; Blount, J. F.; Manchand, P. S. Salvinorin, a new transneoclerodane diterpene from salvia-divinorum (Labiatae). J. Chem. Soc., Perkin Trans. I 1982, 2505-2508.
11. Valdes, L. J., III; Butler, W. M.; Hatfield, G. M.; Paul, A. G.; Koreeda, M. Divinorin A. a psychotropic terpenoid, and divinorin B from the hallucinogenic mexican mint Salvia divinorum. J. Org. Chem. 1984, 49, 4716-4720.
12. Valdes, L. J., III; Diaz, J. L.; Paul, A. G. Ethnopharmacology of skamaria-pastora (salvia, divinorum, epling, and jativa-M). J. Ethnop harmacol. 1983, 7, 287-312.
13. Roth, B. L.; Baner, K.; Westkaemper, R.; Siebert, D.; Rice, K. C.; Steinberg, S.; Ernsberger, P.; Rothman, R. B. Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11934-11939.
14. Butelman, E. R.; Harris, T. J.; Kreck, M. J. The plant-derived hallucinogen, salvinorin A. produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology 2004, 172, 220-224.
15. Butelman, E. R.; Mandau, M.; Tidgewell, K.; Prisinzano, T. E.; Yuferov, V.; Kreck, M. J. Effects of salvinorin A. a κ-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high κ-receptor homology to humans. J. Pharmacol. Exp. Ther. 2007, 320, 300-306.
16. Carlezon, W. A., Jr.; Beguin, C.: Dinieri, J. A.; Baumann, M. H.; Richards, M. R.; Todtenkopf, M. S.; Rothman, R. B.; Ma, Z.; Lee, D. Y.; Cohen, B. M. Depressive-like effects of the κ-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J. Pharmacol. Exp. Ther. 2006, 316, 440-447.
17. McCurdy, C. R.; Sufka, K. J.; Smith, G. H.; Warnick, J. E.; Nieto, M. J. Antinociceptive profile of salvinorin A. a structurally unique kappa opioid receptor agonist. Pharmacol., Biochem. Behav. 2006, 83, 109-113.
18. Fantegrossi, W. E.; Kugle, K. M.; Valdes, L. J., III: Koreeda, M.; Woods, J. H. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A. on inverted screen performance in the mouse. Behav. Pharmacol. 2005, 16, 627-633.
19. John, T. F.; French, L. G.; Erlichman, J. S. The antinociceptive effect of salvinorin A in mice. Eur. J. Pharmacol. 2006, 545, 129-133.
20. Ansonoff, M. A.; Zhang, J.; Czyzyk, T.; Rothman, R. B.; Stewart, J.; Xu, H.; Zjwiony, J.; Siebert, D. J.; Yang, F.; Roth, B. L.; Pintar, J. E. Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of κ-opioid receptor-1 knockout mice. J. Pharmacol. Exp. Ther. 2006, 318, 641-648.
21. Wang, Y.; Tang, K.; Inan, S.; Siebert, D.; Holzgrabe, U.; Lee, D. Y.; Huang, P.; Li, J. G.; Cowan, A.; Liu-Chen, L. Y. Comparison of pharmacological activities of three distinct κ ligands (salvinorin A. TRK-820 and 3FLB) on κ opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J. Pharmacol. Exp. Ther. 2005, 312, 220-230.
22. Kane, B. E.; Nieto, M. J.; McCurdy, C. R.; Ferguson, D. M. A unique-binding epitope for salvinorin A. a non-nitrogenous kappa opioid receptor agonist. FEBS J. 2006, 273, 1966-1974.
23. Vortherms, T. A.; Mosier, P. D.; Westkaemper, R. B.; Roth, B. L. Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity: Studies with salvinorin A and the κ-opioid receptor. J. Biol. Chem. 2007, 282, 3146-3156.
24. Yan, F.; Mosier, P. D.; Westkaemper, R. B.; Stewart, J.; Zjawiony, J. K.; Vortherms, T. A.; Sheffler, D. J.; Roth, B. L. Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to κ-opioid receptors. Biochemistry 2005, 44, 8643-51.
25. Harding, W. W.; Tidgewell, K.; Byrd, N.; Cobb, H.; Dersch, C. M.; Butelman, E. R.; Rothman, R. B.; Prisinzano, T. E. Neoclerodane diterpenes as a novel scaffold for μ opioid receptor ligands. J. Med. Chem. 2005, 48, 4765-4771.
26. Harding, W. W.; Tidgewell, K.; Schmidt, M.; Shah, K.; Dersch, C. M.; Snyder, J.; Parrish, D.; Deschamps, J. R.; Rothman, R. B.; Prisinzano, T. E. Salvinicins A and B, new neoclerodane Diterpenes from Salvia divinorum. Org. Lett. 2005, 7, 3017-3020.
27. Harding, W. W.; Schmidt, M.; Tidgewell, K.; Kannan, P., Holden, K. G.; Gilmour, B.; Navarro, H.; Rothman, R. B.; Prisinzano, T. E. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: Semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A. J. Nat. Prod. 2006, 69, 107-112.
28. Groer, C. E.; Tidgewell, K.; Moyer, R. A.; Harding, W. W.; Rothman, R. B.; Prisinzano, T. E.; Bohn, L. M. An opioid agonist that does not induce μ-opioid receptor - Arrestin interactions or receptor internalization. Mol. Pharmacol. 2007, 71, 549-557.
29. 3]-salvinorin A. Bioorg. Med. Chem. Lett. 2004, 14, 5099-5102.
30. Tidgewell, K.; Harding, W. W.; Lozama, A.; Cobb, H.; Shah, K.; Kannan, P.; Dersch, C. M.; Parrish, D.; Deschamps, J. R.; Rothman, R. B.; Prisinzano, T. E. Synthesis of salvinorin A analogues as opioid receptor probes. J. Nat. Prod. 2006, 69, 914-918.
31. Chavkin, C.; Sud, S.; Jin, W.; Stewart, J.; Zjawiony, J. K.; Siebert, D. J.; Toth, B. A.; Hufeisen, S. J.; Roth, B. L. Salvinorin A. an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious κ-opioid receptor agonist: Structural and functional considerations. J. Pharmacol. Exp. Ther. 2004, 308, 1197-1203.
32. Stewart, D. J.; Fahmy, H.; Roth, B. L.; Yan, F.; Zjawiony, J. K. Bioisosteric modification of salvinorin A. a potent and selective kappa-opioid receptor agonist. Arzneimittelforschung 2006, 56, 269-275.
33. Lamers, Y. M. A. W.; Rusu, G.; Wijnberg, J. B. P. A.; de Groot, A. Synthesis of chiral methyl-branched linear pheromones starting from (+)-aromadendrene. Part 7. Tetrahedron 2003, 59, 9361-9369.
34. Rai, A. N.; Basu, A. Sphingolipid synthesis via olefin cross metathesis: Preparation of a differentially protected building block and application to the synthesis of D-erythro-ceramide. Org. Lett. 2004, 6, 2861-2863.
35. Beguin, C.;: Richards, M. R.; Li, J.-G.; Wang, Y.; Xu, W.; Liu-Chen, L.-Y.; Carlezon, J. W. A.; Cohen, B. M. Synthesis and in vitro evaluation of salvinorin A analogues: Effect of configuration at C(2) and substitution at C(18). Bioorg. Med. Chem. Lett. 2006, 16, 4679-4685.
36. Vaultier, M.; Knouzi, N.; Carrie, R. Reduction d'azides en amines primaires par une methode generale utilisant la reaction de staudinger. Tetrahedron Lett. 1983, 24, 763-764.
37. Bikbulatov, R. V.; Yan, F.; Roth, B. L.; Zjawiony, J. K. Convenien: synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B. Bioorg. Med. Chem. Lett. 2007, 17, 2229-2232.
38. 35S]GTP-γ-S functional binding assay. Synapse 2001, 39, 64-69.
39. Za binding sites. Peptides 1993, 14, 1279-1293.
40. 125I]IOXY). J. Med. Chem. 1992, 35, 2826-2835.
41. Portoghese, P. S. A new concept on the mode of interaction of narcotic analgesics with receptors. J. Med. Chem. 1965, 8, 609-616.
42. Beguin, C.; Potter, D. N.; DiNieri, J. A.; Munro, T. A.; Richards, M. R.; Paine, T. A.; Berry, L.; Zhao, Z.; Roth, B. L.; Xu, W.; Liu-Chen, L.-Y.; Carlezon Jr, W. A.; Cohen, B. M. N-Methylacetamide analogue of salvinorin A: A highly potent and selective kappa opioid receptor agonist with oral efficacy. J. Pharmacol. Exp. Ther. 2008, 324, 188-195.
43. Simpson, D. S.; Katavic, P. L.; Lozama, A.; Harding, W. W : Parrish, D.; Deschamps, J. R.; Dersch, C. M.; Partilla, J. S.; Rothman, R. B.; Navarro, II.; Prisinzano, T. E. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: Preparation and opioid receptor activity of salvinicin analogues. J. Med. Chem. 2007, 50, 3596-3603.
44. Xu, H.; Partilla, J. S.; Wang, X.; Rutherford, J. M.; Tidgewell, K.; Prisinzano, T. E.; Bohn, L. M.; Rothman, R. B. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) μ-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse 2007, 61, 166-175.
45. Eguchi, M. Recent advances in selective opioid receptor agonists and antagonists. Med Res. Rev. 2004, 24, 182-212.
46. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S.; et al. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31, 2235-2246.
47. Bondensgaard, K.; Ankersen, M.; Thogersen, H.; Hansen, B. S.; Wullf, B. S.; Bywater, R. P. Recognition of privileged structures by G-protein coupled receptors. J. Med. Chem. 2004, 47, 888-899.
48. Koehn, F. E.; Carter, G. T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discovery 2005, 4, 206-220.
49. Ortholand, J.-Y.; Ganesan, A. Natural products and combinatorial chemistry: Back to the future. Curr. Opin. Chem. Biol. 2004, 8, 271-280.
50. Luttrell, L. M.; Ferguson, S. S.; Daaka, Y.; Miller, W. E.; Maudsley, S.; Della Rocca, G. J.; Lin, F.; Kawakatsu, H.; Owada, K.; Luttrell, D. K.; Caron, M. G.; Lefkowitz, R. J. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase completes. Science 1999, 283, 655-661.
51. Alm, S.; Nelson, C. D.; Garrison, T. R.; Miller, W. E.; Lefkowitz, R. J. Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 1740-1744.
52. Rothman, R. B.; Murphy, D. L.; Xu, H.; Godin, J. A.; Dersch, C. M.; Partilla, J. S.; Tidgewell, K.; Schmidt, M.; Prisinzano, T. E. Salvinorin A: Allosteric interactions at the μ-opioid receptor. J. Pharmacol. Exp. Ther. 2007, 320, 801-810.
53. Hiebel, A. C.; Lee, Y. S.; Bilsky, E.; Giuvelis, D.; Deschamps, J. R.; Parrish, D. A.; Aceto, M. D.; May, E. L.; Harris, L. S.; Coop, A.; Dersch, C. M.; Partilla, J. S.; Rothman, R. B.; Cheng, K.; Jacobson, A. E.; Rice, K. C. Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent μ-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. J. Med. Chem. 2007, 50, 3765-3776.